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g.2012.0Abstract Hepatitis C virus (HCV) infection is a global health problem in Egypt and causes different
liver disease spectrum. Evidence indicates that angiotensin I converting enzyme (ACE) gene polymor-
phism may play a role in determining disease progression. We aimed to determine the association of
ACE gene I/D polymorphism with ACE serum levels and to examine the association between differ-
ent I/D genotypes with the severity of hepatic ﬁbrosis in chronic HCV infected Egyptian patients.
Thirty controls and 90 HCV infected patients participated in the study, patients were subgrouped
by Ishak stage of ﬁbrosis into subgroup IIa (n= 30; ﬁbrosis score 0–1), subgroup IIb (n= 38; ﬁbro-
sis score 2–3) and subgroup IIc (n= 22; ﬁbrosis score 4–6). DNAwasmultiplied by polymerase chain
reaction (PCR). ACE genotype frequency in HCV infected patients was signiﬁcantly different com-
paring to controls (X2 = 7.169, P= 0.028). With non-signiﬁcant difference in ACE D/I genotypes
and allele frequencies among the patient subgroups (P> 0.05),the frequency of the DD, DI and II
genotypes in subgroup IIa, subgroup IIb and subgroup IIc were (53.3%, 36.6%, 10%), (44.7%,
44.7%, 10.5%) and (50%, 22.7%, 27%), respectively. The D and I allele frequency were (71.66%,
28.33%), (67.1%, 32.9%) and (61.36%, 38.63%), respectively. ACE serum levels were signiﬁcantly
increased in DD more than DI and II (t= 2.56, 3.43, P< 0.05), respectively, with non-signiﬁcant508129407.
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292 A.M.H. Mackawy et al.association in sonographic ﬁndings, viral load and liver function test (LFT) parameters with the ACE
genotypes. Serum ACE levels were signiﬁcantly increased in all patient subgroups when compared to
controls with a non signiﬁcant difference of ACE levels between subgroup IIb and IIc. We concluded
that the D/D genotype is associated with HCV infection but not associated with degree or the pro-
gression of hepatic ﬁbrosis.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
The natural history of the chronic liver disease caused by
HCV remains controversial with varying rates of progression
to cirrhosis [1]. Although approximately 80% of patients
who acquire hepatitis C virus (HCV) infection will develop
a chronic low grade slowly progressive hepatitis, perhaps
only 20–30% of infected patients will progress to clinically
signiﬁcant ﬁbrotic disease after 20–30 years [1]. Hepatic stel-
late cells (HSCs) – the main collagen-producing cells in the
liver, are playing an essential role in ﬁbrogenesis process
[2]. Multiple animal studies suggest that angiotensin II
(AT-II) contributes to hepatic ﬁbrosis. This is primarily
due to induction of proﬁbrotic pathways through the AT-
II receptor type 1 (AT1 receptor) by AT-II, which promotes
the activation of the HSCs [3,4]. Multiple animal model
studies have demonstrated that AT-II-blocking agents, such
as angiotensin-converting enzyme (ACE) inhibitors and
AT-II type 1 receptor antagonist (AT1A), attenuate liver
ﬁbrosis [5]. Experimental animal studies on mice have dem-
onstrated that AT1A receptor-deﬁcient mice are protected
from hepatic ﬁbrosis whereas AT2 receptor-deﬁcient mice
have worse ﬁbrosis [6–8].
The renin–angiotensin system (RAS) is a hormone system
that regulates blood pressure and water balance [9]. It has
been said to be involved in the pathogenesis of several dis-
eases including ﬁbrosis in the liver, kidney, heart and lung
during chronic inﬂammation through the regulation of cell
growth, inﬂammation, oxidative stress and ﬁbrosis [9]. The
ACE gene insertion/deletion (I/D) polymorphism was ﬁrst
identiﬁed in 1990. The gene encoding ACE is located on
chromosome 17q35 and consists of 26 exons. A 250-bp dele-
tion/insertion polymorphism exists in intron 16 of the ACE
gene and the deletion variant is associated with higher serum
levels of the enzyme [10]. The ACE is suggested to be the
key enzyme in the RAS system through converting AT-I
to the potent vasoconstrictor AT-II [11]. The role of the
ACE gene I/D polymorphism as a risk factor has been
investigated in several diseases [12]. The ﬁndings that ACE
inhibitors and AT-II receptor antagonists decrease hepatic
ﬁbrosis support the effects of angiotensin and its receptors
on liver ﬁbrosis [13]. It was found that serum ACE levels
were found to be increased approximately two times in peo-
ple with DD allele of ACE gene [14].
Certain host and environmental factors affecting the
development of ﬁbrosis in chronic HCV infection have been
identiﬁed such as male gender, excess alcohol consumption,
age of acquisition of infection, and obesity [15,16]. However
despite this, it remains difﬁcult to assess an individual’s risk
of developing progressive ﬁbrotic disease. Such prognostic
uncertainty and variation in the response to a common infec-
tive agent suggest a genetic component to the progression of
ﬁbrosis in HCV infection [17].2. Aim of the study
The current study aimed at determining the association of
ACE gene I/D polymorphism with ACE serum levels and
whether there is a signiﬁcant association between different
I/D genotypes with the severity of hepatic ﬁbrosis in chronic
HCV infected Egyptian patients.3. Subjects and methods
This study was carried out in the Medical Biochemistry and
Internal Medicine, Pathology Departments, Faculty of Medi-
cine, Outpatients Clinics and Intensive Care Unit of Zagazig
University Hospitals during the period from June 2010 to
November 2011. In this study we investigated the effect and
relationship of allelic variants of the ACE gene in Egyptian pa-
tients with chronic HCV infection with different degree of liver
ﬁbrosis according to Ishak classiﬁcation [18]. PCR technique
with restriction fragment length polymorphism (RFLP) was
used to detect gene polymorphism.4. Subjects
One hundred and twenty subjects were included in this study.
They were classiﬁed into two main groups:
4.1. Group I
Thirty healthy control volunteers (17 females, 13 males) with
mean ages ± S.D. of 46.76 ± 6.82 years. They are apparently
healthy volunteers not complaining of chronic diseases. Exclu-
sion criteria were positive viral markers (such as hepatitis B and
C), history of alcohol use, diagnosis of autoimmune hepatitis (a
non-resolving inﬂammation of the liver of unknown cause,
characterized by the presence of interface hepatitis on histo-
logic examination, hypergammaglobulinemia, and autoanti-
bodies) [19], or metabolic liver disease (hemochromatosis,
Wilson’s disease, non alcoholic steatohepatitis) [20] liver dis-
ease associated with drug use and primary biliary cirrhosis that
can be diagnosed by symptoms as a general feeling of tiredness,
fatigue, pruritus, dry eyes and mouth and jaundice or can be
diagnosed by laboratory ﬁndings as anti-mitochondrial anti-
body (AMA) blood test, abnormal liver function test (elevated
gamma-glutamyl transferase (GGT) and alkaline phosphatase
(ALP), and abdominal ultrasound that shows whether the liver
and bile ducts are inﬂamed [21].
4.2. Group II ‘‘chronic HCV infection’’
This group included 90 patients (43 females, 47 males) with
mean ages ± S.D. of 49.25 ± 6.7 years. They did not receive
any treatment of hepatitis C virus before the study. They
Table 1 Comparison of clinical and laboratory data of the all studied groups (mean ± S.D. and range, with Anova test).
Group I Subgroup IIa Subgroup IIb Subgroup IIc F value
N= 30 N= 30 N= 38 N= 22 P value
Sex 17 Females 16 Females 18 Females 9 Females F= 0.489
13 Males 14 Males 20 Males 13 Males P= 0.690
Age (years)Range 46.76 ± 6.82 48.1 ± 6.11 49.07 ± 7.15 51.13 ± 6.96 F= 1.94
37.0–58.0 39.0–59.0 40.00–62.0 38.00–63.0 P= 0.126
Serum ACE (U/L) 64.65 ± 16.85 112.86 ± 15.61 180.77 ± 36.57 185.95 ± 21.44 F= 155.69
39.50–98.0 69.70–143.00 110.70–243.60 133.7–218.5 P= 0.000
Serum ALT (IU/L) 23.9 ± 6.48 89.8 ± 22.01 131.71 ± 36.58 120.81 ± 30.97 F= 99.0
15.00–34.0 45.0–123.0 76.0–254.0 76.0–189.0 P= 0.000
Serum AST (IU/L) 23.23 ± 5.26 108.93 ± 34.08 138.71 ± 38.22 140.0 ± 34.05 F= 93.13
13.0–33.0 56.0–199.0 75.0–200.0 87.0–199.0 P= 0.000
Serum ALP (IU/L) 25.33 ± 7.52 34.40 ± 9.37 32.55 ± 8.88 33.63 ± 7.09 F= 7.26
15.0–40.0 22.0–56.00 20.0–51.0 23.0–51.0 P= 0.000
Serum albumin g/dl 4.04 ± 0.55 3.04 ± 0.58 2.96 ± 0.64 2.89 ± 0.64 F= 23.54
3.2–5.2 2.2–4.2 2.00–4.2 2.00–4.00 P= 0.000
T.bilirubin mg/dl 0.96 ± 0.33 1.95 ± 0.42 1.89 ± 0.40 1.92 ± 0.41 F= 43.35
0.30–1.60 1.20–2.90 1.0–2.70 1.10–2.87 P= 0.000
Viral load Eq/ml – 350 · 103–2 · 106 950 · 103–555 · 104 55 · 105–2 · 107 F= 106.276
1 · 106 ± 416.720 2970 · 103 ± 1.319.142 10.300 · 103 ± 4.464.734 P= 0.000
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as HCV infected patients. HCV infection was diagnosed as
+ve ELISA for anti HCV antibodies. The presence of anti-
HCV antibodies was determined in serum samples by enzyme
linked immunosorbent assay technique (ELISA) and +ve
PCR for HCV-RNA tested by reverse transcription polymer-
ase chain reaction (RT-PCR) performed on patient sera using
Amplicor (Roche Diagnostics, Lewes, UK). All liver biopsy
specimens were taken under guided ultrasonography and
graded for the degree of necro-inﬂammatory activity and
staged for the extent of ﬁbrosis according to the criteria of
Ishak classiﬁcation [18]. History of risk factors for HCV
infection and alcohol consumption were established. Dura-
tion of infection at the time of liver biopsy was also recorded.
The study was approved by Zagazig University Ethics
Committee. Informed consent was obtained from all patients
before participation in this study. The characteristics of both
control and studied patient subgroups are listed in Table 1.
5. Sample collection
Ten milliliters fasting venous blood samples were collected
from the subjects using standardized protocol and equipment,
separated into two samples one whole blood for DNA extrac-
tion and ACE gene polymorphism determination and the other
serum sample for estimation of ACE levels and other liver
function test (LFT) parameters. They were measured by
standard chemical and enzymatic commercial methods in the
Medical Biochemistry Department, Zagazig University.
5.1. Methods
All subjects are submitted to the followings:
(1) Fullmedical history takingandcomplete clinical examination.
(2) Abdominal ultrasonography examination with evalua-
tion of different hepatobiliary parameters including
portal, hepatic and mesenteric vein diameters.
(3) Liver biopsy for patients with chronic HCV infection.
(4) Laboratory investigations including:(A) Routine investigations:(*) Liver function tests:– Serum alanine transaminase (ALT), aspartate transam-
inase (AST) and alkaline phosphatase (ALP) using bio-
Merieux kit [22].
– Serum total bilirubin levels [23].
– Serum albumin using photometric colorimetric test [24].
(\) Viral hepatitis markers: HCV antibodies by ELISA,
HCV RNA–RT-PCR and HBs Ag and another hepatotro-
pic virus (A).
– Hepatitis biopsy specimen should contain four pieces of
information to most completely assess the specimen and
serve patient care [18]:
(1) The statement that it is, indeed, chronic hepatitis.
(2) The grade of activity (including the name of the scoring
system used).
(3) The stage of activity (including the name of the scoring
system used).
(4) The known or suspected cause of the hepatitis.
(5) Hepatitis related changes (hepatitis C-related fat, increased
iron uptake, large cell and small cell changes) and particu-
larly common concomitant diseases, such as alcoholic and
nonalcoholic fatty liver disease and hemochromatosis.
6. Laboratory analysis
– Estimation of serum ACE levels using spectrophotometric
assay [25].
– ACE gene polymorphism by PCR technique [26,27].
6.1. ACE gene I/D genotyping
Genomic DNA to be used in molecular analysis was isolated
and prepared from leucocytes using Biospin Blood Genomic
DNA Mini-prep Kit (Sigma, Aldrich Co. LLC, NA2000).
Figure 1 Number of group II patients according to Ishak
classiﬁcation.
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tron of ACE gene, was performed with PCR. The PCR was
performed in a Perkin Elmer 4800 thermal cycler (PTC-100
machine, MJ Research, Inc., Watertown, Mass. USA). For
each PCR reaction the reaction mix prepared as the end vol-
ume had to be 25 ll by using 10 pmol/lL.
F 50CTGGAGACCACTCCCATCCTTTCT30 and R50GA
TGTGGCCATCACATTCGTCAGAT30 primers, contained
4 dNTP (Roche-Almanya), 10XPCR tamponade (100 mM
Tris–HCl, 15 mM MgCl2, 500 mM KCl, pH: 8.3) (Roche-
Almanya), 1.25U Taq DNA Polymerase and 100 ng genomic
DNA with a concentration of 30 lmol/ml. Reaction was per-
formed in 35 cycles each composed of denaturation in 95 C
for 5 min, annealing in 94 C for 30 s and extension in 69 C
for 45 s. After DNA ampliﬁcation, PCR products were taken
on 2% agarose gel electrophoresis and analyzed under UV
transilluminator (Illuminyx UVB Transilluminator, USA) by
staining 0.5 lg/ml ethidium bromide. Running conditions were
70 V, 100 mA and140 min. 100 Base-Pair Ladder (Bioron) was
0.2 mg/ml in 10 Mm Tris (pH 8.0), 1 mM EDTA. Sub-marine
gel electrophoresis was used (Pharmacia Biotech by SEMKO
AB, Sweden) using submarine chamber (Maxicell, EC 360
M-E-C apparatus Cooperation ST. Petersburg. Florida,
USA). PCR method resulted in a 190 bp product that showed
deletion (D allele) and in the presence of insertion, produced a
490 bp product (I allele). In heterozygous samples, two bands
of 490 and 190 bp were detected [26,27].
6.2. Statistical analysis
Results were statistically analyzed using SPSS version 11.5 for
Windows. The statistical data were calculated for mean and
standard deviation (S.D.). Analysis of variance (ANOVA)
was used to compare the results of all examined cases in all
studied groups within group comparisons. The differences be-
tween mean values for each element were tested by student’s
‘‘t’’ test. The Hardy–Weinberg equilibrium or odds ratio
(OR) and 95% conﬁdence interval (CI) for the presence of
HCV infection and different liver ﬁbrosis grades within the
ACE genotypes were analyzed by using the chi square v2 test.
Results were considered signiﬁcant when P< 0.05 [25,28].
7. Results
Ninety chronicHCV infected patients (43 females, 47males with
mean ages of 49.25 ± 6.7 years) and 30 controls (13males, 17 fe-
males with mean ages of 46.76 ± 6.82 years) were evaluated in
this study. Anova test (F-test) revealed a non-signiﬁcant differ-
ence between groups regarding sex and age (F= 0.489,
P= 0.690 and F= 1.94, P= 0.126), respectively as illustrated
in Table 1.
7.1. Fibrosis scores (Fig. 1)
– Ishak classiﬁcation subgrouped the group II patients
according to the stage of liver ﬁbrosis on liver biopsy
into three subgroups as follows (Fig. 1).
– Subgroup IIa ‘‘HCVwith ﬁbrosis score 0 or 1’’: This sub-
group comprised 30 patients (33.33%) with ages ranged
between 39.0 and 59.0 years with a mean value ± S.D.
of 48.1 ± 6.11 years (16 females and 14 males).– Subgroup IIb: ‘‘HCV with ﬁbrosis score 2 or 3’’: This
subgroup included 38 patients (42.22%) (18females
and 20 males) with ages ranged from 40.00 to 62.0 years
with a mean value ± S.D. of 49.07 ± 7.15 years.
– Subgroup IIc: ‘‘HCV with ﬁbrosis score 4 or 6’’: This
subgroup comprised 22 patients (24.44%) (9 females
and 13 males) with ages ranged between 38.00 and
63.0 years with a mean value ± S.D. of 51.13 ±
6.96 years.
There was no statistical difference between all groups
regarding age and sex (P> 0.05).
7.2. Distribution of polymorphism of ACE gene
The frequency of ACE I/D genotypes is summarized in Table 2
and Fig. 2.
In controls and patients with chronic HCV infection (group
II), the frequency of D and I allele was 33 (55%) and 27 (45%)
and 121 (67.22%) and 59 (32.78%), respectively. The fre-
quency of D allele was more frequent in group II patients
but this increase was non-signiﬁcant when compared to con-
trols (X2 = 2.924, P= 0.061 with OR= 0.596 with 95% CI
of 0.328–1.082). The DD, DI and II genotypes were recorded
in controls and group II patients as follows 7 (23.33%), 19
(63.33%), 4 (13.33%) and 44 (48.8%), 33 (36.6%) and 13
(14.4%, respectively. However, there was a signiﬁcant associa-
tion of genotype frequency in HCV infected patients (group II)
when compared to the controls (X2 = 7.169, P= 0.028), we
referred this non-signiﬁcant result in D and I allele frequency
between control and group II to the relatively small sample
of the current study.
However, results recorded a non-signiﬁcant difference in
ACE D/I genotypes and allele frequencies between the chronic
HCV patient subgroups (Tables 2 and 3).
– In subgroup IIa: The homozygous DD was detected in 16
patients (53.3%), the heterozygous DI in 11 patients (36.6%)
and the homozygous II in 3 patients (10%). The D and I allele
frequency were 71.66% and 28.33%, respectively.
– In subgroup IIb: There were 17 patients (44.7%) of homo-
zygous DD genotype and there were similar number of
patients with DI genotype, we found only 4 (10.5%) patients
carrying the homozygous II genotype. The D and I allele fre-
quency were 67.1% and 32.9%, respectively.
Figure 3 Mean of serum ACE levels in ACE genotypes in all
studied groups.
Table 2 Allele and genotype frequencies for ACE polymorphism in all studied groups.
Groups Genotype frequency n (%) Allele frequency n (%)
DD DI II D I
Group I 7 (23.33%) 19 (63.33%) 4 (13.33%) 33 (55%) 27 (45%)
Group II 44 (48.8%) 33 (36.6%) 13 (14.4%) 121 (67.22%) 59 (32.78%)
Subgroup IIa 16 (53.3%) 11 (36.6%) 3 (10%) 43 (71.66%) 17 (28.33%)
Subgroup IIb 17 (44.7%) 17 (44.7%) 4 (10.5%) 51 (67.1%) 25 (32.9%)
Subgroup IIc 11 (50%) 5 (22.7%) 6 (27%) 27 (61.36%) 17 (38.63%)
Figure 2 Frequency of different ACE genotypes in all studied
groups.
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DI and homozygous II genotypes were detected in 11 patients
with chronic HCV infection (50%), 5 patients (22.7%) and 6
patients (27%), respectively. The D and I allele frequency were
61.36% and 38.63%, respectively.
We revealed a non-signiﬁcant association with ACE gene
(I/D) polymorphism among chronic HCV infected patients
(P> 0.05), the distribution of ACE genotype was similar be-
tween subgroups as illustrated in Table 2.
SerumACE and the viral load mean ± S.D. levels related to
different groups are listed in Table 1. The different genotypes in
each group showed different means ± S.D. of ACE serum lev-
els (Fig. 3), however the ultrasonographic ﬁndings [right liver
(cm), superior mesenteric vein diameter (mm) and portal vein
diameter (mm)] and viral load values (Eq/ml) recorded nonsig-
niﬁcant differences among different ACE D/I genotypes of
group II (HCV infected patients) listed in Table 4.
ANOVA test (F-test) revealed a signiﬁcant difference of the
mean values of serum ACE level and viral load values among
different studied groups (F= 155.69 and F= 106.276,
P= 0.000), respectively. Serum ACE levels were signiﬁcantlyTable 3 Chi square and OR (95% CI) of ACE genotypes and allel
Groups ACE genotype D and
Control group vs group II X2 = 7.169 X2 = 2
P= 0.028 P= 0
Subgroup IIa vs subgroup IIb X2 = 0.525 X2 = 0
P= 0.769 (NS) P= 0
Subgroup IIa vs subgroup IIc X2 = 3.01 X2 = 1
P= 0.22 (NS) P= 0
Subgroup IIb vs subgroup IIc X2 = 4.26 X2 = 0
P= 0.118 (NS) P= 0higher in patients with chronic HCV infection than controls
(t= 13.816, P= 0.000). On comparing serum ACE levels
among HCV infected patient subgroups, their levels were sig-
niﬁcantly increased in subgroup IIb and subgroup IIc more
than subgroup IIa (t= 11.01, t= 13.05, P= 0.00), respec-
tively, with non-signiﬁcant difference between two subgroups
IIb and IIc (t= 1.286, P= 0.212).
Viral load values recorded signiﬁcant increase in subgroup
IIc and subgroup IIb patients more when compared to sub-
group IIa with signiﬁcant increase in subgroup IIc more than
subgroup IIb patients (t= 9.738, t= 8.109 and t= 7.637,
P= 0.000), respectively.
Data of Table 4 revealed that there was a signiﬁcant in-
crease in the serum ACE levels in control subjects and patients
with chronic HCV infection carrying the DD genotype com-
pared to subjects of DI and II genotypes in all studied groups
(P< 0.05).
7.3. Data of liver function test (LFT) is listed in Table 1
Regarding serum ALT, AST levels there was a signiﬁcant in-
crease in group II patients with chronic HCV infection when
compared to controls (t= 16.96, t= 13.29, P= 0.000),
respectively.e frequency in all studied groups.
I allele frequency OR of D and I allele frequency 95% CI
.924 0.596
.061 (0.05) 0.328–1.082
.327 1.240
.582 (NS) 0.593–2.593
.22 1.59
.296 (NS) 0.697–3.641
.404 1.284
.556 (NS) 0.593–2.782
Table 4 Serum ACE levels (U/L), ultrasonographic and viral load (Eq/ml) of different genotypes in all studied groups.
Groups DD DI II t-Value P value
n= 7 n= 19 n= 4
Group I (controls) ACE range (U/L) 76.0–98.0 43.0–77.40 39.50–48.60 4.248*
9.288**
P= 0.005
P= 0.003Mean ± S.D. 88.02 ± 8.22 60.47 ± 10.14 43.57 ± 3.92
Group II (HCV patients) DD
n= 44
DI
n= 33
II
n= 13
2.558*
3.43**
P= 0.015
P= 0.005
ACE range (U/L) 110.0–243.60 100.80–234.0 69.70–133.70
Mean ± S.D. 178.24 ± 9.70 153.6 ± 36.81 108.76 ± 20.03
Group II: liver right lobe (cm) range: mean ± S.D. 12.8–18.8
15.73 ± 1.55
12.5–19.2
15.77 ± 1.58
13.7–18.4
15.86 ± 1.65
0.611*
0.401**
0.342***
P= 0.546
P= 0.696
P= 0.738
Group II: superior mesenteric vein diameter (mm) range: mean ± S.D. 7.5–14.6 8.9–13.7 9.6–13.6 1.870*
0.405**
0.201***
P= 0.071
P= 0.692
P= 0.844
10.44 ± 1.74 11.22 ± 1.33 10.92 ± 1.23
Group II: portal vein diameter (mm) range
Mean ± S.D.
10.1–17.8 10.1–18.1 13.7–17.6 0.745*
2.044**
1.87***
P= 0.462
P= 0.063
P= 0.085
14.65 ± 2.17 14.82 ± 2.01 15.77 ± 1.33
Group II: viral load range: mean ± S.D. (Eq/ml) 380 · 103–20 · 106 350 · 103–20 · 106 500 · 103–10 · 106 1.226*
0.172**
0.951***
P= 0.229
P= 0.866
P= 0.361
3340 · 103 ± 368.706 4340 · 103 ± 515.983 5840 · 103 ± 390.342
* Referred to t-value of comparing DD with DI.
** t-Value of comparing DD with II.
*** t-Value of comparing DI with II ACE genotypes.
2
9
6
A
.M
.H
.
M
a
ck
a
w
y
et
a
l.
Table 5 Laboratory parameter levels and Anova (F-test) with different ACE genotypes in all studied groups.
DD DI II F value
N= 51 N= 52 N= 17 P value
Serum ALT levels (IU/L) 102.86 ± 45.73 80.19 ± 54.99 97.52 ± 43.11 F= 2.793
15.00–254.0 15.0–199.0 17.0–200.0 P= 0.065
Serum AST (IU/L) 103.27 ± 56.82 102.17 ± 61.71 97.58 ± 33.71 F= 0.065
13.0–200.0 16.0–200.0 19.0–134.0 P= 0.937
Serum ALP (IU/L) 32.46 ± 8.01 30.98 ± 9.33 29.88 ± 11.15 F= 0.353
20.0–55.0 15.0–51.00 16.0–56.0 P= 0.703
Serum albumin (g/dl) 3.18 ± 0.73 3.16 ± 0.71 3.65 ± 0.89 F= 2. 67
2.0–5.2 2.0–4.0 2.00–5.10 P= 0.065
Serum T. bilirubin (mg/dl) 1.59 ± 0.64 1.81 ± 0.46 1.55 ± 0.63 F= 2.43
0.30–2.90 1.00–2.87 0.30–2.30 P= 0.092
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subgroups, there was a signiﬁcant increase in subgroup IIb and
subgroup IIc than subgroup IIa patients (t= 5.123, t= 3.371,
t= 2.641, t= 2.117, P< 0.05), respectively, with non-signif-
icant difference between subgroup IIb and subgroup IIc
(t= 0.88, t= 0.131, P> 0.05).
Serum ALP and T. bilirubin levels were signiﬁcantly in-
creased in group II patients than controls (t= 4.30, t=
9.12, P = 0.000), respectively, with non-signiﬁcant difference
among all patient subgroups (P> 0.05). Serum albumin levels
showed signiﬁcant decrease in group II patients than controls
(t= 6.28, P= 0.000), with non-signiﬁcant change among
patient subgroups (P> 0.05). Table 5 illustrated that there
was a non-signiﬁcant association between all LFT parameters
and the genotype pattern of the ACE gene (P> 0.05).8. Discussion
Egypt has the largest epidemic of HCV in the world. The re-
leased Egyptian Demographic Health Survey revealed that
the percentage of HCV infection in Egypt was 14.7% [29].
Hepatitis C was generally found to be worse, both with greater
severity of activity and more rapidly advancing ﬁbrosis [30].
Subsequent to successful long-term maintenance of immune
competence, this expectation of worse or more rapid injury is
not necessarily reﬂected by the biopsy specimens that now
come from patients with coinfection [31].
Hepatic stellate cells (HSC) are thought to play a pivotal
role in ﬁbrogenesis within the liver, and there is a large body
of evidence to support the hypothesis that Angiotensin II
(Ang-II) promotes activation and dedifferentiation of these
cells into myoﬁbroblasts [32]. Furthermore, Ang II encourages
myoﬁbroblast contraction, proliferation and promotes release
of inﬂammatory cytokines as well as the deposition of extracel-
lular matrix (ECM) [33]. Although both of the Ang II recep-
tors (AT1 and AT2) are expressed in the liver, the AT1
receptor is far in abundance and is thought to be responsible
for most of the Ang II-mediated effects [34]. Multiple studies
have shown that angiotensin-receptor blockade leads to
downregulation of pro-inﬂammatory/proﬁbrotic cytokines
and postulated that inhibition of angiotensin II decreases the
generation of reactive oxygen species, resulting in less collagen
synthesis by HSCs, and downregulates the vascular endothelial
growth factor, thus attenuating ﬁbrosis [35]. Angiotensin-1 A(AT1A) receptor knockout mice have demonstrated reduced
liver ﬁbrosis compared with wild-type mice in a carbon tetra-
chloride model [36].
A great deal of evidence supporting the role of the renin–
angiotensin system (RAS) in hepatic ﬁbrosis has come from
animal studies using ACE inhibitors and angiotensin receptor
blockers (ARB). Numerous studies using a variety of animal
models have demonstrated antiﬁbrotic effects of these drugs
[36,37].
These researches’ results and evidences of the fundamental
role of RAS in the regulation of hepatic ﬁbrosis guided us to
examine the possible effect of D/I SNP of ACE gene as a com-
ponent of RAS gene upon ﬁbrosis in chronic HCV infection
among Egyptians. In our present study, patients with chronic
HCV infection showed a signiﬁcant increase in DD genotype
when compared to the controls, the frequency of D allele
was increased in group II patients but this increase was not sig-
niﬁcant, we speculated this non-signiﬁcance may be referred to
the small number of our patient sample. Moreover, a non-sig-
niﬁcant association was determined between DD, DI and II
genotype frequency of ACE gene and ﬁbrosis stage among pa-
tients with chronic HCV infection (P> 0.05).
These ﬁndings were in concordance with Mohamed et al.
[38], who recorded signiﬁcant higher percentage of HCV Egyp-
tian patients having the I/D and DD genotypes than the
healthy controls.
Forrest et al. [39] studied different four polymorphisms of
RAS gene and could not identify any signiﬁcant association
between these four RAS polymorphisms and ﬁbrosis in
chronic HCV infection. In addition another study of Gu¨c¸lu¨
et al. [40] suggested that ACE gene had no role in the develop-
ment of ﬁbrosis in non-alcoholic fatty liver disease.
Serejo et al. [41] recorded that DD genotype was signiﬁ-
cantly more prevalent among chronic hepatitis C (CHC) pa-
tients but in contrast to our results they declared that ACE I
allele may be a risk factor for liver ﬁbrosis progression.
Our ﬁndings also revealed a signiﬁcant association between
the increase in the frequency of D allele of ACE gene and ACE
serum levels, patients carrying the DD genotype were having a
signiﬁcant increase in serum ACE levels (P< 0.05) but this
genotype have a non-signiﬁcant association with each of ultr-
asonographic ﬁndings, viral load values and other LFT param-
eters (P> 0.05).
In concert with our results, Samani et al. [42], Baudin [43]
and Gunes et al. [44] have found that plasma ACE levels were
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and myocardial infarction patients, respectively.
In contrast to our results, Powell et al. [45] and Forrest et
al. [39] reported a non-signiﬁcant correlation between ACE
activity and ACE genotype in chronic HCV. Moreover, Bu¨lent
et al. [46] failed to ﬁnd any signiﬁcant association between ser-
um ACE levels and ACE gene I/D polymorphism genotypes in
patients with Osteoarthritis.
We reported a signiﬁcant increase in serum ACE levels and
other LFT parameters in chronic HCV infected patients
compared to controls but we failed to record any signiﬁcant dif-
ference among different ﬁbrosis stages in HCV infected patient
subgroups except for viral load values which recorded a signif-
icant increase in subgroup IIc and subgroup IIb more than sub-
group IIa patients meaning that the viral load may play a
pivotal role in hepatic ﬁbrosis progression. Previous studies
have also detected increased serum ACE levels in patients with
chronic liver disease, but they have suggested that ACE activity
is an effective discriminator of the severity of liver disease
[47,48]. This was not matched with our results as we could
not ﬁnd any signiﬁcant association between ACE genotypes’
distribution and the different ﬁbrosis stages in patients with
chronic HCV infection and even the serum ACE levels did
not show any signiﬁcant differences in patient subgroups.
Meaning that we could not rely on ACE D/I gene polymor-
phism, ACE serum levels or other liver function test parame-
ters to determine the deﬁnitive stage of ﬁbrosis or suspect
the course or the severity of the disease in HCV infected pa-
tients. But these observations cannot mask the potential
importance of RAS in the hepatic ﬁbrogenesis. However, it
does suggest that whatever be the mechanism of the increased
expression of the ACE levels in DD genotype carrier in chronic
HCV infection but that does not suspect the severity and the
course of ﬁbrotic liver disease in HCV infection.
These conﬂicting and opposing results may be explained by
the several genetic polymorphisms which exist in the RAS and
some of these are recognized to account for the inter-individual
variation in RAS activity [39].
However, the pathological risk of ACE DD genotypes also
varies between populations with different genetic and environ-
mental backgrounds, suggesting that the ACE DD genotype is
acting as a disease modiﬁer rather than as a disease susceptibil-
ity factor [43].
Different studies show that AT-II increased liver ﬁbrosis via
HSCs, which are activated in damaged liver and a target for
AT-II by expressing AT-I receptors in cell surface, while
AT-II had no effect on normal healthy liver [32,33,34].
Bulent et al. [47] recorded an increase in the frequency of DD
genotype in individuals with fatty liver causing higher levels of
serum AT-II levels but no association with necro-inﬂammation
or the level of liver ﬁbrosis suggesting that high frequency of
AT-II related with DD genotype prepared a background for
disease progression in association with fattening which is the
ﬁrst move and that it is not responsible for direct progression.
Several genetic polymorphisms in the RAS exist and some
of these are recognized to account for inter-individual varia-
tion in RAS activity and this mechanism might account for
the variable rate of progression observed in chronic HCV
infection [39,49,50,51].
In conclusion, we found an association between ACE D/I
gene polymorphism, DD genotype and ACE serum levels with
HCV infection but we have been unable to identify anyassociation between ACE genotype and the development or
the progression of ﬁbrosis in chronic HCV infection. The fre-
quency of D/D genotype was higher in chronic HCV patient
group but it did not have any effect on necro-inﬂammatory
activity and ﬁbrosis stage. However, it should be noted that
these conﬂicting results of our study and other different studies
are referred to relatively small sample studies and the absence
of hepatitis C virus genotype as the results of this study indicate
that HCV genotype 4 in Egypt is extremely variable, not only in
terms of sequence, but also in terms of functional and immuno-
logical determinants [52,53]. Adequate larger sample studies
must be undertaken for more explanation of the suspected role
of ACE gene polymorphism and different RAS component
polymorphisms should be examined in the development and
progression of ﬁbrosis in HCV to solve this issue. It seems that
other factors such as environmental factors and viral load may
play a more signiﬁcant role in this process.References
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